Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 15/20 | 0.67 |
| ▸ | JAK2 | O60674 | 5/20 | 0.64 |
| ▸ | JAK3 | P52333 | 4/20 | 0.64 |
| ▸ | JAK1 | P23458 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169516 | 0.93 | PLK4 (0.56) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL3691748 | 0.92 | JAK1 (0.73) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL3698982 | 0.89 | JAK2 (0.72) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL13189226 | 0.87 | PLK4 (0.74) | PLK4JAK2 | |
| SCHEMBL13169815 | 0.85 | PLK4 (0.73) | PLK4JAK2JAK3 | |
| SCHEMBL13169473 | 0.84 | PLK4 (0.70) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL13169567 | 0.84 | PLK4 (0.78) | PLK4JAK2 | |
| SCHEMBL13169511 | 0.84 | PLK4 (0.52) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL15466084 | 0.83 | PLK4 (0.68) | PLK4JAK2JAK3JAK1 | |
| SCHEMBL13170020 | 0.83 | PLK4 (0.68) | PLK4JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885JAK2 3/4885JAK3 1/4885 |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885JAK2 3/4885JAK3 1/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885JAK2 3/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.